| 157 | 14 | 44 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨生脉胶囊联合盐酸埃克替尼片对晚期非小细胞肺癌患者靶向治疗的临床疗效。方法收集2016年1月至2018年1月期间收治的晚期非小细胞肺癌患者94例,按照随机数字表法分为对照组与观察组,各47例。对照组患者予盐酸埃克替尼片125 mg,po,tid;观察组在对照组基础上予生脉胶囊0.9 g,po,tid。2组疗程均为8周。评估或测量治疗前后生存质量、肿瘤标志物(癌胚抗原CEA和糖类抗原CA125)水平、不良反应、中位无进展生存期(PFS)和临床疗效。结果治疗后,观察组总有效率高于对照组(74.46%vs 53.19%,P<0.05),血清CEA和CA125水平低于对照组(P<0.05),不良反应发生率低于对照组(14.89%vs 42.55%,P<0.05),中位PFS长于对照组[(10.32±1.87)月vs(7.43±1.28)月,P<0.05]。结论生脉胶囊联合盐酸埃克替尼片对晚期非小细胞肺癌患者靶向治疗近期疗效良好,且可延长患者无进展生存期。
Abstract：AIM To investigate the clinical efficacy of the Shengmai capsule combined with icotinib hydrochloride tablets in the targeted treatment of advanced non-small cell lung cancer. METHODS The 94 patients with advanced non-small cell lung cancer admitted from January 2016 to January 2018 were divided into control group(n=47) and observation group(n=47) according to random number table method. The control group was treated with the icotinib hydrochloride tablets(125 mg, po, tid), while the observation group was treated with Shengmai capsule(0.9 g, po, tid) on the basis of the control group. The course of treatment in both groups was 8 weeks. The therapeutic effects, adverse drug reactions and median progression free survival(PFS) were compared between the 2 groups, and the changes of quality of life and tumor markers were compared before and after treatment. RESULTS The total effective rate of the observation group was higher than that of the control group(74.46% vs 53.19%,P<0.05). The levels of serum carcinoembryonic antigen(CEA) and carbohydrate antigen 125(CA125) in the observation group were lower than those in the control group before treatment(P<0.05). The adverse drug reaction rate in the observation group was lower than that in the control group(14.89% vs 42.55%,P<0.05). PFS in the observation group was longer than that in the control group [(10.32±1.87)mon vs(7.43±1.28)mon,P<0.05]. CONCLUSION Shengmai capsule combined with icotinib hydrochloride tablets has a good short-term therapeutic effect on advanced non-small cell lung cancer patients, and can prolong the progression-free survival of patients.
[1] JAMAL-HANJANI M,WILSON G A,McGRANAHAN N,et al.Tracking the evolution of non-small-cell lung cancer[J].N Engl J Med,2017,376(22):2109.
[2] 张梦希,于文军,任春玲,等.三种含铂类化疗方案治疗晚期非小细胞肺癌的疗效和药物经济学分析[J].中国基层医药,2017,24(14):2088.
[3] MOK T S,WU Y L,AHN M J,et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J].N Engl J Med,2017,376(7):629.
[4] 陈蕊,赵达,王丽娜.非小细胞肺癌EGFR-TKI耐药机制及治疗策略[J].肿瘤防治研究,2017,44(3):225.
[5] 郭雷鸣,丁高峰,葛红,等.放疗联合EGFR-TKI治疗非小细胞肺癌EGFR-TKI治疗后新发骨转移疗效观察[J].中华实用诊断与治疗杂志,2017,31(11):1112.
[6] 刘华丽,许斌,韩光,等.EGFR-TKI在非小细胞肺癌中的研究进展[J].中国肿瘤,2018,27(4):285.
[7] 中华人民共和国卫生部医政司.中国常见恶性肿瘤诊治规范[S].北京:北京医学大学中国协和医学大学联合出版社,1991:94-98.
[8] HIRSCH F R,McELHINNY A,STANFORTH D,et al.PD-L1 immunohistochemistry assays for lung cancer:results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J].J Thorac Oncol,2017,12(2):208.
[9] SORIA J C,TAN D,CHIARI R,et al.First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4):a randomised,open-label,phase 3 study[J].Lancet,2017,389(10072):917.
[10] MASTERS G A,TEMIN S,AZZOLI C G,et al.Systemic therapy for stage IV non-small-cell lung cancer:American society of clinical oncology clinical practice guideline update[J].J Oncol Pract,2017,33(30):832.
[11] 周云,万丹影,钱晓倩,等.榄香烯注射液联合吉非替尼改善表皮生长因子受体突变非小细胞肺癌晚期患者免疫功能及生活质量的效果[J].中国临床保健杂志,2017,20(5):502.
[12] 王阿曼,宁振,刘基巍.非小细胞肺癌EGFR-TKI耐药的分子机制及防治策略[J].中华肿瘤防治杂志,2017,24(1):71.
[13] 鹿楠楠,潘跃银,韩兴华.三种EGFR-TKI药物治疗晚期肺癌疗效及预后因素的回顾性研究[J].现代肿瘤医学,2018,26(15):55.
[14] 张明.肿瘤标志物联合检测在肺癌中的应用研究[J].国际检验医学杂志,2017,38(11):1569.
[15] 陈天明,余国辉,李任翔,等.化疗对晚期肺癌患者肿瘤标志物水平变化的影响[J].实用临床医药杂志,2017,21(13):29.
[16] 李利英,武云利,李双平.血清肿瘤标志物在肺癌TNM分期中的价值研究[J].临床和实验医学杂志,2017,16(13):1309.
基本信息:
DOI：10.19577/j.1007-4406.2020.04.002
中图分类号:R734.2
引用信息:
[1]吕群,陆秀婷,阮肇扬,等.生脉胶囊联合盐酸埃克替尼片对晚期非小细胞肺癌患者靶向治疗的临床疗效[J].中国临床药学杂志,2020,29(04):244-247.DOI:10.19577/j.1007-4406.2020.04.002.
基金信息:
浙江省医学会临床科研基金(编号2017ZYC-A32)
2020-07-25
2020-07-25